Table 3.
Overall survival | Cox regression | ||||
---|---|---|---|---|---|
Characteristic | N ◦ at start | N ◦ deaths | P-value * | HR (95%CI) | P ◦ |
Age at transplantion (ys) | |||||
≤ 55 | 10 | 4 | 0.27 | ||
> 55 | 10 | 7 | |||
Age at cancer diagnosis (ys) | |||||
≤ 64 | 10 | 3 | 0.09 | ||
> 64 | 10 | 8 | |||
Transplant-cancer interval (ys) | |||||
≤ 8.6 | 10 | 6 | 0.47 | ||
> 8.6 | 10 | 5 | |||
PSA at diagnosis (ng/ml) | |||||
<10 | 17 | 8 | 1 | ||
>10 | 3 | 3 | 0.029 | 4.25 (1.04–17.4) | 0.044 |
Bioptic gleason score | |||||
≤7 | 15 | 7 | 0.43 | ||
>7 | 5 | 4 | |||
Pathologic gleason score | |||||
≤7 | 7 | 2 | 0.35 | ||
>7 | 3 | 1 | |||
cT stage | |||||
2 | 12 | 6 | 0.82 | ||
3 | 8 | 5 | |||
Primary therapy | |||||
Surgery | 10 | 3 | 0.061 | ||
RT | 10 | 8 | |||
Hormonotherapy | |||||
No | 18 | 9 | 0.41 | ||
Yes | 2 | 2 | |||
Post-surgery RT | |||||
No | 17 | 8 | 0.59 | ||
Yes | 3 | 3 | |||
Other cancers | |||||
No | 9 | 4 | 0.71 | ||
Yes | 11 | 7 | |||
Biochemical recurrence | |||||
No | 17 | 9 | 0.79 | ||
Yes | 3 | 2 | |||
Immunosuppresive therapy | |||||
Other | 17 | 9 | |||
Cyclosporine+steroid+azathioprine | 3 | 2 | 0.24 | ||
Gleason Score group at transrectal ultrasound biopsy | |||||
GS 6 (3 + 3) | 8 | 6 | |||
GS 7 (3 + 4) | 4 | 0 | 0.49 | ||
GS 7 (4 + 3) | 3 | 1 | |||
GS 8 (4 + 4) | 3 | 3 | |||
GS 9 (4 + 5) | 2 | 1 | |||
Gleason Score group after open radical prostatectomy | |||||
GS 6 (3 + 3) | 5 | 1 | |||
GS 7 (3 + 4) | 2 | 1 | 0.34 | ||
GS 8 (4 + 4) | 1 | 0 | |||
GS 9 (4 + 5) | 2 | 1 | |||
Total | 20 | 11 |
Ys, years; RT, radiotherapy; GS, Gleason score.
P-value from log rank test;
p-value from Cox regression analysis.
They represent the Hazard Ratio (HR), the 95% Confidence Interval (CI) and the p value from Cox regression analysis.